Replimune's Stock Plummets After FDA Rejects RP1 Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 29 2024
0mins
Should l Buy REPL?
Source: investopedia.com
Replimune Group Inc. shares fell 56.51% as the company hit a 52-week low following the FDA's rejection of its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma.
The FDA's complete response letter indicated insufficient data for approval, leading to significant operational challenges for Replimune, including potential layoffs and reduced manufacturing capacity. Jefferies downgraded the stock from 'Buy' to 'Hold', slashing the price target from $13 to $2, reflecting a pessimistic outlook on the company's future after the FDA's decision.
This rejection not only impacts Replimune's immediate financial health but also raises concerns about its long-term viability in the competitive melanoma treatment landscape, leaving patients with fewer options and the company facing increased scrutiny from investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.950
Low
3.00
Averages
11.43
High
18.00
Current: 1.950
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
- FDA Rejection Impact: Replimune's RP1 melanoma therapy received a Complete Response Letter (CRL) from the FDA, indicating significant hurdles in obtaining market approval, which could lead to a decline in future revenue expectations for the company.
- Analyst Downgrades: Following the FDA rejection, analysts have sharply cut their ratings and price targets for Replimune, reflecting a pessimistic sentiment regarding the company's future prospects, which may further undermine investor confidence.
- Review Process Dispute: Replimune has disputed the FDA's review process, claiming unfairness, which could lead to further communications with the regulatory body and impact the company's future approval strategies.
- Negative Market Reaction: The combination of the FDA rejection and negative analyst feedback may put pressure on Replimune's stock price, prompting investors to closely monitor how the company addresses this challenge to restore market confidence.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Replimune Shares Hit All-Time Low After FDA Rejection
- FDA Rejection: Replimune's melanoma drug RP1 received a Complete Response Letter from the FDA on April 10, causing shares to plummet to an all-time low of $1.50 on Monday, reflecting a negative market sentiment towards the company's future prospects.
- Analyst Downgrades: J.P. Morgan, BMO Capital Markets, and Wedbush have all downgraded Replimune, with BMO's Evan David Seigerman setting a price target of $1, indicating a lack of confidence in RP1's potential for approval.
- Clinical Trial Uncertainty: Analysts noted that the FDA expressed concerns regarding Replimune's BLA resubmission, particularly criticizing the single-arm trial design and efficacy assessment methods used in the RPL-001-16 trial, which raises the risk of RP1's future approval.
- Severe Market Reaction: Following the FDA's rejection, Replimune's stock fell by 56% on Monday, demonstrating a significant loss of investor confidence that could adversely affect the company's financing and research capabilities.
See More
Trump Threatens 50% Tariff on China Amid Trade Tensions
- Tariff Threat Escalation: President Trump threatened a staggering 50% tariff on China during a Fox News interview, which could significantly impact multinational companies like Apple that rely heavily on Chinese supply chains, further escalating trade tensions.
- Increased Economic Risks: This tariff threat not only poses operational challenges for global retail giants like Nike but also raises investor concerns about the economic repercussions of the ongoing Middle East conflict, adding layers of uncertainty to the market.
- Market Reaction: Although Trump labeled the underlying reports as potentially 'fake news', the market's reaction indicates a heightened sensitivity among investors regarding future trade relations, which could lead to increased volatility in stock prices.
- Geopolitical Implications: Against the backdrop of rising tensions in the Middle East, Trump's tariff threat introduces new risks to the global economy, potentially affecting U.S.-China diplomatic relations and their competitiveness in international markets.
See More
Replimune's RP-1 Faces Second FDA Rejection, Shares Plunge
- FDA Rejection Impact: The FDA's second rejection of Replimune's melanoma treatment RP-1 has led to a staggering 60% drop in pre-market trading, pushing the stock to a record low and highlighting significant regulatory hurdles threatening the company's future.
- Analyst Downgrade: Jefferies downgraded Replimune from 'Buy' to 'Hold' and slashed its price target to $2 from $13, a nearly 85% reduction, indicating a pessimistic outlook on the company's path forward following the FDA's decision.
- Job Cuts Risk: Following the FDA's rejection, Replimune warned of potential operational cutbacks and job losses, reflecting the severe financial challenges the company faces amid increasing uncertainty surrounding RP-1's development.
- Market Sentiment Fluctuation: Despite the sharp decline in stock price, retail investor sentiment on Stocktwits remains 'extremely bullish', with message volumes surging over 2000% in the past 24 hours, indicating continued interest in Replimune despite the negative news.
See More
U.S. Stock Futures Drop as Oil Prices Surge Above $100 Amid Iran Tensions
- Market Reaction to Tensions: U.S. stock futures fell Monday morning as investors reacted to the breakdown in peace talks between the U.S. and Iran, indicating heightened sensitivity to geopolitical risks in the market.
- Oil Price Surge: President Trump’s threat of a military blockade in the Strait of Hormuz quickly pushed oil prices back above $100 a barrel, a level that could have widespread implications for the global economy.
- Baker Hughes Stock Rise: Baker Hughes (BKR) shares rose by 2% after agreeing to sell its Waygate Technologies unit to Hexagon AB for approximately $1.45 billion in cash, a strategic move aimed at streamlining its portfolio and enhancing earnings stability.
- Children's Place Stock Plunge: Children's Place (PLCE) shares tumbled 16% following a disappointing Q4 marked by a 19.4% year-over-year sales decline to $329 million, reflecting ongoing challenges with weak e-commerce traffic and reduced consumer demand.
See More
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
- FDA Rejection Impact: Replimune's RP1 melanoma therapy received a Complete Response Letter (CRL) from the FDA, indicating significant hurdles in obtaining market approval, which could lead to a decline in future revenue expectations for the company.
- Analyst Downgrades: Following the FDA rejection, analysts have sharply cut their ratings and price targets for Replimune, reflecting a pessimistic sentiment regarding the company's future prospects, which may further undermine investor confidence.
- Review Process Dispute: Replimune has disputed the FDA's review process, claiming unfairness, which could lead to further communications with the regulatory body and impact the company's future approval strategies.
- Negative Market Reaction: The combination of the FDA rejection and negative analyst feedback may put pressure on Replimune's stock price, prompting investors to closely monitor how the company addresses this challenge to restore market confidence.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Replimune Shares Hit All-Time Low After FDA Rejection
- FDA Rejection: Replimune's melanoma drug RP1 received a Complete Response Letter from the FDA on April 10, causing shares to plummet to an all-time low of $1.50 on Monday, reflecting a negative market sentiment towards the company's future prospects.
- Analyst Downgrades: J.P. Morgan, BMO Capital Markets, and Wedbush have all downgraded Replimune, with BMO's Evan David Seigerman setting a price target of $1, indicating a lack of confidence in RP1's potential for approval.
- Clinical Trial Uncertainty: Analysts noted that the FDA expressed concerns regarding Replimune's BLA resubmission, particularly criticizing the single-arm trial design and efficacy assessment methods used in the RPL-001-16 trial, which raises the risk of RP1's future approval.
- Severe Market Reaction: Following the FDA's rejection, Replimune's stock fell by 56% on Monday, demonstrating a significant loss of investor confidence that could adversely affect the company's financing and research capabilities.
See More
Trump Threatens 50% Tariff on China Amid Trade Tensions
- Tariff Threat Escalation: President Trump threatened a staggering 50% tariff on China during a Fox News interview, which could significantly impact multinational companies like Apple that rely heavily on Chinese supply chains, further escalating trade tensions.
- Increased Economic Risks: This tariff threat not only poses operational challenges for global retail giants like Nike but also raises investor concerns about the economic repercussions of the ongoing Middle East conflict, adding layers of uncertainty to the market.
- Market Reaction: Although Trump labeled the underlying reports as potentially 'fake news', the market's reaction indicates a heightened sensitivity among investors regarding future trade relations, which could lead to increased volatility in stock prices.
- Geopolitical Implications: Against the backdrop of rising tensions in the Middle East, Trump's tariff threat introduces new risks to the global economy, potentially affecting U.S.-China diplomatic relations and their competitiveness in international markets.
See More
Replimune's RP-1 Faces Second FDA Rejection, Shares Plunge
- FDA Rejection Impact: The FDA's second rejection of Replimune's melanoma treatment RP-1 has led to a staggering 60% drop in pre-market trading, pushing the stock to a record low and highlighting significant regulatory hurdles threatening the company's future.
- Analyst Downgrade: Jefferies downgraded Replimune from 'Buy' to 'Hold' and slashed its price target to $2 from $13, a nearly 85% reduction, indicating a pessimistic outlook on the company's path forward following the FDA's decision.
- Job Cuts Risk: Following the FDA's rejection, Replimune warned of potential operational cutbacks and job losses, reflecting the severe financial challenges the company faces amid increasing uncertainty surrounding RP-1's development.
- Market Sentiment Fluctuation: Despite the sharp decline in stock price, retail investor sentiment on Stocktwits remains 'extremely bullish', with message volumes surging over 2000% in the past 24 hours, indicating continued interest in Replimune despite the negative news.
See More
U.S. Stock Futures Drop as Oil Prices Surge Above $100 Amid Iran Tensions
- Market Reaction to Tensions: U.S. stock futures fell Monday morning as investors reacted to the breakdown in peace talks between the U.S. and Iran, indicating heightened sensitivity to geopolitical risks in the market.
- Oil Price Surge: President Trump’s threat of a military blockade in the Strait of Hormuz quickly pushed oil prices back above $100 a barrel, a level that could have widespread implications for the global economy.
- Baker Hughes Stock Rise: Baker Hughes (BKR) shares rose by 2% after agreeing to sell its Waygate Technologies unit to Hexagon AB for approximately $1.45 billion in cash, a strategic move aimed at streamlining its portfolio and enhancing earnings stability.
- Children's Place Stock Plunge: Children's Place (PLCE) shares tumbled 16% following a disappointing Q4 marked by a 19.4% year-over-year sales decline to $329 million, reflecting ongoing challenges with weak e-commerce traffic and reduced consumer demand.
See More
